Collegium Pharmaceutical (COLL) Competitors

$36.08

+0.66 (+1.86%)

(As of 07/26/2024 ET)

COLL vs. SVA, STML, INZY, NKTR, SPPI, RNA, CRNX, IMVT, ACLX, and XENE

Should you be buying Collegium Pharmaceutical stock or one of its competitors? The main competitors of Collegium Pharmaceutical include Sinovac Biotech (SVA), Stemline Therapeutics (STML), Inozyme Pharma (INZY), Nektar Therapeutics (NKTR), Spectrum Pharmaceuticals (SPPI), Avidity Biosciences (RNA), Crinetics Pharmaceuticals (CRNX), Immunovant (IMVT), Arcellx (ACLX), and Xenon Pharmaceuticals (XENE). These companies are all part of the "medical" sector.

Collegium Pharmaceutical vs.

Sinovac Biotech (NASDAQ:SVA) and Collegium Pharmaceutical (NASDAQ:COLL) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, analyst recommendations, community ranking, profitability, earnings, risk, media sentiment, institutional ownership and valuation.

: Collegium Pharmaceutical has higher revenue and earnings than Sinovac Biotech.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Sinovac Biotech $448.27M 1.44 -$99.92M N/A N/A
Collegium Pharmaceutical $566.77M 2.08 $48.15M $2.40 15.03
: In the previous week, Collegium Pharmaceutical had 3 more articles in the media than Sinovac Biotech. MarketBeat recorded 4 mentions for Collegium Pharmaceutical and 1 mentions for Sinovac Biotech. Sinovac Biotech's average media sentiment score of 0.94 beat Collegium Pharmaceutical's score of 0.00 indicating that Collegium Pharmaceutical is being referred to more favorably in the news media.
Company Overall Sentiment
Sinovac Biotech Neutral
Collegium Pharmaceutical Positive
: Collegium Pharmaceutical received 120 more outperform votes than Sinovac Biotech when rated by MarketBeat users. However, 67.99% of users gave Sinovac Biotech an outperform vote while only 65.22% of users gave Collegium Pharmaceutical an outperform vote.
Company Underperform Outperform
Sinovac Biotech Outperform Votes
257
67.99%
Underperform Votes
121
32.01%
Collegium Pharmaceutical Outperform Votes
377
65.22%
Underperform Votes
201
34.78%
: Collegium Pharmaceutical has a net margin of 16.46% compared to Collegium Pharmaceutical's net margin of 0.00%. Sinovac Biotech's return on equity of 104.98% beat Collegium Pharmaceutical's return on equity.
Company Net Margins Return on Equity Return on Assets
Sinovac Biotech N/A N/A N/A
Collegium Pharmaceutical 16.46% 104.98% 18.00%
: Collegium Pharmaceutical has a consensus price target of $40.75, indicating a potential upside of 12.94%. Given Sinovac Biotech's higher probable upside, analysts plainly believe Collegium Pharmaceutical is more favorable than Sinovac Biotech.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Sinovac Biotech
0 Sell rating(s)
0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
N/A
Collegium Pharmaceutical
0 Sell rating(s)

3 Hold rating(s)

2 Buy rating(s)

0 Strong Buy rating(s)
2.40

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sinovac Biotech	$448.27M	1.44	-$99.92M	N/A	N/A
Collegium Pharmaceutical	$566.77M	2.08	$48.15M	$2.40	15.03

Company	Overall Sentiment
Sinovac Biotech	Neutral
Collegium Pharmaceutical	Positive

Company	Underperform	Outperform
Sinovac Biotech	Outperform Votes 257 67.99%	Underperform Votes 121 32.01%
Collegium Pharmaceutical	Outperform Votes 377 65.22%	Underperform Votes 201 34.78%

Company	Net Margins	Return on Equity	Return on Assets
Sinovac Biotech	N/A	N/A	N/A
Collegium Pharmaceutical	16.46%	104.98%	18.00%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sinovac Biotech	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	N/A
Collegium Pharmaceutical	0 Sell rating(s)	3 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.40

Summary

Collegium Pharmaceutical beats Sinovac Biotech on 11 of the 12 factors compared between the two stocks.

Ad WealthPress

This TSLA short trade is on a nine win hot streak

Most Tesla Shareholders are disappointed in the stock's performance in 2024. Year to date, it's down 30%... And things don’t seem to be getting better. That said, one professional trader has found a way to turn Tesla’s demise into a flurry of opportunity… In fact, he has not lost a single trade on Tesla this year. As of this mailing he’s 9 for 9 with incredible wins under his belt. Just see for yourself.

But I can promise that you’ll see all the details for yourself here.

Get Collegium Pharmaceutical News Delivered to You Automatically

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding COLL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

COLL vs. The Competition

Export to Excel

Metric	Collegium Pharmaceutical	Pharmaceutical Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.18B	$7.05B	$5.31B	$8.19B
Dividend Yield	N/A	2.82%	2.72%	3.96%
P/E Ratio	15.03	20.22	152.08	18.37
Price / Sales	2.08	291.03	2,071.74	88.82
Price / Cash	3.19	32.58	35.89	34.13
Price / Book	6.02	5.89	4.95	4.51
Net Income	$48.15M	$147.89M	$112.29M	$216.36M
7 Day Performance	11.50%	2.90%	2.73%	1.82%
1 Month Performance	11.22%	9.07%	6.97%	7.09%
1 Year Performance	67.42%	4.24%	11.22%	4.88%

Collegium Pharmaceutical Competitors List

Export to Excel

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SVA Sinovac Biotech	0 of 5 stars 0.00 / 5 stars	$6.47 flat	N/A	N/A	$644.67M	$448.27M	0.00	3,261	Upcoming Earnings High Trading Volume
STML Stemline Therapeutics	0 of 5 stars 0.00 / 5 stars	$11.83 flat	N/A	+0.0%	$621.21M	$43.22M	-7.44	92
INZY Inozyme Pharma	1.2937 of 5 stars 1.29 / 5 stars	$5.79 +1.6%	$16.00 +176.3%	+6.0%	$358.17M	N/A	-4.23	59	Analyst Forecast News Coverage Gap Up
NKTR Nektar Therapeutics	3.7377 of 5 stars 3.74 / 5 stars	$1.37 -2.8%	$3.00 +119.0%	+157.5%	$252.11M	$90.12M	-1.49	137	Short Interest ↑
SPPI Spectrum Pharmaceuticals	0 of 5 stars 0.00 / 5 stars	$1.03 flat	N/A	N/A	$211.41M	$10.11M	-2.86	86	Analyst Forecast
RNA Avidity Biosciences	0.1219 of 5 stars 0.12 / 5 stars	$44.72 +0.2%	$44.29 -1.0%	+417.1%	$4.28B	$9.56M	-15.16	190	Insider Selling Short Interest ↑ News Coverage
CRNX Crinetics Pharmaceuticals	3.8635 of 5 stars 3.86 / 5 stars	$53.34 -0.1%	$64.08 +20.1%	+188.2%	$4.21B	$4.01M	-14.11	210	Insider Selling Short Interest ↑ News Coverage
IMVT Immunovant	1.1448 of 5 stars 1.14 / 5 stars	$27.80 -0.5%	$49.73 +78.9%	+35.3%	$4.06B	N/A	-14.63	120	Options Volume
ACLX Arcellx	1.5656 of 5 stars 1.57 / 5 stars	$62.69 +1.0%	$78.00 +24.4%	+90.2%	$3.35B	$110.32M	-60.86	80
XENE Xenon Pharmaceuticals	2.2503 of 5 stars 2.25 / 5 stars	$43.85 +0.3%	$59.11 +34.8%	+22.8%	$3.31B	$9.43M	-16.18	210	Options Volume News Coverage Positive News